Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

NIMBLE WOMENTECHEU

financed

Closed

A novel non-invasive and non-ionizing medical device for monitoring patients wit...

A novel non-invasive and non-ionizing medical device for monitoring patients with implanted stents Susana Amorós is the CTO and co-founder of NIMBLE Diagnostics, a MedTech company developing a first in class microwave-based medical device for the continuos, non-invasive, non-ionizing monitoring of patients with implanted stents... see more

31/05/2024

NIMBLE DIAGNOSTICS...

75K€

Project Budget: 75K€

Project leader

NIMBLE DIAGNOSTICS Fabricación de equipos de radiación, electromédicos y electroterapéuticos sociedad limitada

TRL 8-9

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2024-05-31

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU Expected Outcome:Project results are expected to contribute to the following expected outcomes:

Innovación

Cerrada

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

NIMBLE DIAGNOSTICS

75.00K€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 12 months Date Start: 2023-05-26
End date: 2024-05-31

Project leader

NIMBLE DIAGNOSTICS Fabricación de equipos de radiación, electromédicos y electroterapéuticos sociedad limitada

TRL 8-9

Project Budget 75K€

participation deadline Sin fecha límite de participación.

Project description Susana Amorós is the CTO and co-founder of NIMBLE Diagnostics, a MedTech company developing a first in class microwave-based medical device for the continuos, non-invasive, non-ionizing monitoring of patients with implanted stents. Stents are one of the most implanted devices worldwide and are used to restore the correct flow of blood or other fluids. They are especially useful to prevent heart attacks or to treat their lasting symptoms, but once implanted can become blocked or damaged, which occur in 30% of the cases. The symptoms only appear after a stent is already 90% dysfunctional, which increases the incidence of serious complications, including strokes, heart attacks or sudden death. The standard-of-care is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery. This complex procedure is not standardized for recurrent monitoring, not allowing clinicians to act upon the problem until it has already manifested. The NIMBLE System can read the electromagnetic signature of the stent non-invasively, providing information on stent satus and malfunction that can be correlated with relevant clinical outcomes. Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of pharmacological therapy, shifting from reactive to proactive care. Our technology is currently at TRL5 with an MVP that has shown and excellent results in on-going validations. However, before we can offer our solution to cardiologists and primary care clinicians, we must complete key activities in our action plan. WomenTechEU will help us to better understand pricing and reimbursement strategies for the NIMBLE System in European markets, gain visibility with investors and collaborators, and support and mentoring from being one of the growing numbers of female entrepreneurs. Susana expects that this program supports her in bringing NIMBLE System to the market.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers